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A lysosomal storage disease (LSD) results from deficient lysosomal enzyme activity, thus the substrate of the mutant
enzyme accumulates in the lysosome, leading to pathology. In many but not all LSDs, the clinically most important
mutations compromise the cellular folding of the enzyme, subjecting it to endoplasmic reticulum–associated
degradation instead of proper folding and lysosomal trafficking. A small molecule that restores partial mutant enzyme
folding, trafficking, and activity would be highly desirable, particularly if one molecule could ameliorate multiple
distinct LSDs by virtue of its mechanism of action. Inhibition of L-type Ca
2þ channels, using either diltiazem or
verapamil—both US Food and Drug Administration–approved hypertension drugs—partially restores N370S and
L444P glucocerebrosidase homeostasis in Gaucher patient–derived fibroblasts; the latter mutation is associated with
refractory neuropathic disease. Diltiazem structure-activity studies suggest that it is its Ca
2þ channel blocker activity
that enhances the capacity of the endoplasmic reticulum to fold misfolding-prone proteins, likely by modest up-
regulation of a subset of molecular chaperones, including BiP and Hsp40. Importantly, diltiazem and verapamil also
partially restore mutant enzyme homeostasis in two other distinct LSDs involving enzymes essential for glycoprotein
and heparan sulfate degradation, namely a-mannosidosis and type IIIA mucopolysaccharidosis, respectively.
Manipulation of calcium homeostasis may represent a general strategy to restore protein homeostasis in multiple
LSDs. However, further efforts are required to demonstrate clinical utility and safety.
Citation: Mu TW, Fowler DM, Kelly JW (2008) Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium
homeostasis PLoS Biol 6(2): e26. doi:10.1371/journal.pbio.0060026
Introduction
Cells usually maintain a balance between protein synthesis,
folding, trafﬁcking, aggregation, and degradation—which is
referred to as protein homeostasis—by using sensors and
networks of pathways [1,2]. Human loss-of-function diseases
are often the result of a disruption of normal protein
homeostasis, which is typically caused by a mutation in a
given protein that compromises its cellular folding, leading to
efﬁcient degradation [3]. Thus, there is insufﬁcient function,
because the concentration of the mutant protein is exceed-
ingly low.
There are at least 40 distinct lysosomal storage diseases
(LSDs) resulting from the deﬁcient function of a single
mutated enzyme in the lysosome, leading to accumulation of
corresponding substrate(s) [4,5]. Currently, LSDs are treated
by enzyme replacement therapy, which can be challenging
because the endocytic system has to be used to get the
recombinant enzyme into the lysosome [6].
The most prevalent LSD is Gaucher disease (GD), which is
caused by a deﬁciency in the activity of lysosomal glucocer-
ebrosidase (GC), a glycolipid hydrolase [7]. Glucosylceramide
accumulation in Gaucher monocyte-macrophage cells leads
to hepatomegaly, splenomegaly, anemia, thrombocytopenia,
bone lesions, and in severe cases, central nervous system
(CNS) involvement [8]. Patients without CNS involvement are
classiﬁed as type I (mild adult onset), whereas those with CNS
involvement are classiﬁed as type II (acute infantile onset) or
type III (subacute juvenile or early adult onset). The clinically
most important GC mutations, such as N370S, the most
common mutation associated with type I GD, and L444P, the
most prevalent mutation resulting in CNS involvement,
predispose GC to misfold in the endoplasmic reticulum
(ER), subjecting these variants to ER-associated degradation
(ERAD), reducing the normal amount of mutant GC trafﬁck-
ing to the lysosome. Thus, the mutant GC concentration in
the lysosome is substantially reduced [9,10]. Many of the
folding-deﬁcient GC variants exhibit fractional speciﬁc
activity when properly folded [11], demonstrating that if
folding and trafﬁcking of the mutated enzymes could be
enhanced, it is likely that the disease would be ameliorated.
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PLoS BIOLOGYThe US Food and Drug Adminidtration (FDA) has
approved enzyme replacement therapy and substrate reduc-
tion therapy to treat type I GD [5,12]. There is currently no
effective treatment for neuropathic GD (types II and III); the
recombinant GC enzyme does not cross the blood–brain
barrier and the efﬁcacy of the substrate reduction drug in the
CNS remains unclear, hence a novel strategy for neuropathic
GD would be welcomed. Pharmacological chaperoning is an
emerging therapeutic strategy that uses ER-permeable small
molecules that bind to and stabilize the folded state of a given
enzyme, enabling its trafﬁcking to the Golgi and onward to
the lysosome [13–23]. Whereas patient-derived cells harbor-
ing most GD-associated mutations appear to be amenable to
pharmacological chaperoning, cell lines harboring the L444P
GC mutation have thus far proven refractory, although
alternative dosing regimens could ultimately be useful [17].
a-Mannosidosis and type IIIA mucopolysaccharidosis
(MPS) are neuropathic LSDs caused by the inability of the
lysosome to degrade glycoproteins and heparan sulfate,
respectively [5,24,25]. The P356R mutation in lysosomal a -
mannosidase alters the folding energy landscape resulting in
severe infantile a-mannosidosis associated with rapid mental
deterioration [26]. The prevalent S66W or R245H heparan
sulfate sulfamidase (SGSH) mutations in type IIIA MPS
reduce mutant enzyme concentrations in the lysosome, most
likely due to impaired folding and ERAD in lieu of efﬁcient
folding and trafﬁcking of sulfamidase, leading to the
accumulation of heparan sulfate and severe CNS degener-
ation [27]. Currently no effective therapy is available for a-
mannosidosis or type IIIA MPS, hence new strategies for
these neuropathic LSDs would be welcomed.
The Ca
2þ ion is a universal and extremely important
signaling ion in the cell. Ca
2þ signaling affects numerous
cellular functions by diverse pathways and is a primary
regulator of ER function [28–30]. Emerging evidence indicates
that calcium signaling may inﬂuence diseases associated with
deﬁciencies in protein homeostasis, including many LSDs
[4,31,32]. This hypothesis is supported by observations that
manipulation of calcium homeostasis by sarcoplasmic endo-
plasmic reticulum Ca
2þ-ATPase (SERCA) inhibitors, such as
thapsigargin [33] and curcumin [34], enhances folding and
trafﬁcking of the DF508 cystic ﬁbrosis transmembrane
conductance regulator (CFTR).
The hypothesis that manipulation of intracellular calcium
homeostasis might improve defects in mutant enzyme
homeostasis that lead to LSDs was scrutinized. Small
molecules were sought that enhance the folding, trafﬁcking,
and function of endogenous mutant lysosomal enzymes in
multiple cell lines associated with different LSDs, thus
restoring function by repairing instead of replacing the
damaged enzyme through altering calcium homeostasis. In
this quest, we discovered that the FDA-approved drugs
diltiazem and verapamil, both L-type voltage-gated calcium
channel blockers [35], partially restored mutant lysosomal
enzyme function in three distinct LSDs caused by folding
defects in nonhomologous enzymes. These results suggest that
calcium channel blockers are promising candidates to
enhance lysosomal enzyme homeostasis in a variety of LSDs,
although more investigation is necessary to demonstrate
clinical utility and safety.
Results
The L-type Ca
2þ Channel Blockers Diltiazem and
Verapamil Enhance Lysosomal GC Activity in Gaucher
Patient-Derived Fibroblast Cell Lines
Several type I, II, and III Gaucher ﬁbroblast cell lines were
evaluated to discern the relative activity of the mutant GC
harbored by equal numbers of cells reﬂected by an equal
amount of total protein in the cell lysate. The residual
enzymatic activities of the GC variants were measured using
the lysed cell activity assay (Figure 1A). Under the assay
conditions used, L444P GC exhibits 12% of the activity of
wild-type (WT) GC; N370S GC, 32%; N370S/V394L GC, 28%;
N370S/84GG GC, 19%; and G202R GC, 10% of the activity of
WT GC. The exact enzyme activity measured is highly
dependent on the assay conditions [17]. The enzyme activities
displayed were normalized to the activity of untreated cells of
the same type and expressed as fold changes. In addition,
mutant GC activity before and after treatment was also
expressed as the percentage of WT GC activity to calibrate
the reader.
Gaucher patient–derived ﬁbroblasts harboring the L444P
GC mutation grown at 30 8C, instead of at 37 8C, exhibit
enhanced folding, trafﬁcking, lysosomal localization, and
activity of L444P GC [10]. Because a change in temperature
alters both the physical chemistry of the L444P protein and
the cellular protein homeostasis machinery, the hypothesis
that cells were readjusting their protein homeostasis capacity
through their thermosensitive transient receptor potential
(TRP) channels was tested. Fifteen thermosensitive TRP
channel modulators (capsaicin, resiniferatoxin, piperine,
olvanil, anandamide, 2-APB, camphor, 4a-PDD, menthol,
eucalyptol, icilin, cinnamaldehyde, allylisothiocyanate, cap-
sazepine, and ruthenium red) were administered to homo-
zygous L444P GC patient–derived ﬁbroblasts [36,37].
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Author Summary
Lysosomes are organelles that contain more than 50 hydrolytic
enzymes that break down macromolecules in a cell. A lysosomal
storage disease results from deficient activity of one or more of
these enzymes, leading to the accumulation of corresponding
substrate(s). Currently, lysosomal storage diseases are treated by
enzyme replacement therapy, which can be challenging because the
enzyme has to enter the cell and the lysosome to function; in
neuropathic diseases, enzyme replacement is not useful because
recombinant enzymes do not enter the brain. We have shown that
diltiazem and verapamil, potent US Food and Drug Administration–
approved L-type Ca
2þ channel blocker drugs, increased the
endoplasmic reticulum (ER) folding capacity, trafficking, and activity
of mutant lysosomal enzymes associated with three distinct
lysosomal storage diseases. These compounds appear to function
through a Ca
2þ ion–mediated up-regulation of a subset of
cytoplasmic and ER lumenal chaperones, possibly by activating
signaling pathways that mitigate cellular stress. We have shown that
increasing ER calcium levels appears to be a relatively selective
strategy to partially restore mutant lysosomal enzyme homeostasis
in diseases caused by the misfolding and degradation of non-
homologous mutant enzymes. Because diltiazem crosses the blood–
brain barrier, it may be useful for the treatment of neuropathic
lysosomal storage diseases, and possibly other loss-of-function
diseases, although efficacy needs to be demonstrated.Figure 1. Influence of Small Molecules on GC Variant Activity in Gaucher Patient-Derived Fibroblasts
(A) Residual activities of GC variants using the lysed cell GC activity assay, using equal numbers of cells as ascertained from the equal total protein
content of the lysate. Residual activities of N370S, N370S/V394L, N370S/84GG, L444P, and G202R GC are shown as the percentage of WT GC activity
(numbers above each column).
(B) Chemical structures of diltiazem (compound 1) and verapamil.
(C) The influence of diltiazem (1) on L444P GC activity in three distinct homozygous L444P GC patient-derived cell lines: L444P GC fibroblasts from a
type II patient (left panel), another type II patient (middle panel), and a type III patient (right panel). These cell lines were cultured with diltiazem for 5 d
(green line) and 7 d (orange line). The GC activity of treated cells was normalized against that of untreated cells of the same type (left y-axis) and
expressed as the percentage of WT GC activity (right y-axis).
(D) The influence of diltiazem on N370S GC activity in homozygous N370S/N370S GC fibroblasts (left panel), heterozygous N370S/V394L fibroblasts
(middle panel), and heterozygous N370S/84GG fibroblasts (right panel). These cell lines were cultured with diltiazem for 3 d (pink line), 5 d (green line),
and 7 d (orange line). The GC activity of treated cells was normalized against that of untreated cells of the same type (left y-axis) and expressed as the
percentage of WT GC activity (right y-axis).
(E) The influence of diltiazem on WT and G202R GC activity. WT and G202R GC cell lines were cultured with diltiazem for 5 d. The GC activity was
expressed as the percentage of WT GC activity.
(F) The influence of verapamil on L444P and N370S/V394L GC activity. These cell lines were treated with verapamil for 7 d. The GC activity was expressed
as the percentage of WT GC activity.
doi:10.1371/journal.pbio.0060026.g001
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from increased lysosomal L444P GC activity measured using
the intact cell GC enzyme assay. Only ruthenium red notably
increased L444P GC activity after a 5-d incubation period
(Figure S1). Because the only TRP channel modulator that
enhanced lysosomal L444P GC activity was also a nonspeciﬁc
Ca
2þ channel blocker, the observed increase might be a
consequence of a lowered intracellular Ca
2þ ion concen-
tration, and thus it seemed unlikely that TRP channel
modulation is the means by which temperature regulates
the intracellular protein homeostasis capacity.
The hypothesis that ruthenium red was lowering the
intracellular Ca
2þ ion concentration and enhancing GC
folding ﬁdelity by that means was scrutinized experimentally
by blocking calcium entry into the cell through its calcium
channels, including voltage-gated calcium channels (VGCCs)
and ionotropic glutamate receptors [28,38,39]. Lysosomal
L444P GC activity was evaluated after the separate applica-
tion of nine representative VGCC blockers—namely diltia-
zem, verapamil, nifedipine, nimodipine, loperamide,
mibefradil, ethosuximide, ﬂunarizine, and bepridil—ﬁve
representative ionotropic glutamate receptor inhibitors—
namely CGP 39551, 5,7-dichlorokynurenic acid, DNQX, Evans
blue, and felbamate—and other calcium channel blockers—
such as amiodarone, cinnarizine, and SKF 96365—to L444P
GC patient-derived ﬁbroblasts. The intact cell GC activity
assay revealed that only diltiazem and verapamil (chemical
structures shown in Figure 1B) increased L444P GC activity
signiﬁcantly. Diltiazem increased L444P GC activity a
maximum of 2.0-fold (to ’24% of normal cellular WT GC
activity) after a 5-d incubation period, and 2.3-fold after a 7-d
incubation period (Figure 1C, left panel) at a 10 lM
concentration (all concentrations mentioned are cell culture
concentrations unless otherwise stated), implying an in-
creased lysosomal L444P GC concentration. The temporal
dependence of the diltiazem-mediated cellular L444P GC
activity increase is very similar to the time dependence of the
cellular N370S GC activity increase observed upon pharma-
cological chaperone treatment [17]. The slow gain in activity
of the GC variants is partially a result of the slower folding
and trafﬁcking of the variants as revealed by prior pulse chase
experiments [18,40] and partially for other reasons, including
the apparent requirement for the transcription and trans-
lation of selected chaperones (vide infra). This slow mutant
GC activity increase upon pharmacological chaperone or
diltiazem administration is also observed upon pharmaco-
logical chaperone administration in different LSDs such as
Fabry disease, Tay-Sachs disease, and Pompe disease
[13,20,41].
To conﬁrm that the effect of diltiazem was not restricted to
one L444P GC patient-derived cell line, two additional
patient-derived homozygous L444P GC ﬁbroblast cell lines
were treated with diltiazem. In a type II cell line, diltiazem (15
lM) increased the GC activity up to 2.0-fold after an
incubation period of 5 d and up to 2.5-fold after 7 d of
treatment (Figure 1C, middle panel). Diltiazem (10 lM)
treatment of a type III Gaucher patient-derived cell line
increased L444P GC activity to a maximum of 2.1-fold after a
5-d incubation period and up to 2.3-fold after a 7-d
incubation period (Figure 1C, right panel). Lysosomal
L444P GC activity was improved in all the neuropathic
ﬁbroblast cell lines evaluated.
If diltiazem regulates mutant GC homeostasis by a general
mechanism, such as a cellular chaperone–mediated mecha-
nism, and not by binding induced pharmacological chaper-
oning, it should also be able to enhance the folding,
trafﬁcking and activity of other misfolding-prone GC variants
in homozygous and compound heterozygous Gaucher pa-
tient-derived cell lines. Diltiazem (10 lM) increased N370S
GC activity up to 2.0-fold (to ’64% of untreated WT GC
activity) after a 5-d incubation period and up to 2.5-fold after
a 7-d incubation period in N370S GC ﬁbroblasts from a
homozygote (Figure 1D, left panel), analogous to the best
results obtained with optimized pharmacological chaperones
[22]. In the case of a compound heterozygous N370S/V394L
GC cell line, diltiazem (10 lM) increased the GC activity up to
3.2-fold (to ’89% of cellular WT GC activity) after an
incubation period of 5 d and up to 3.7-fold after 7 d of
treatment (Figure 1D, middle panel). In the analogous N370S/
84GG GC cell line, diltiazem (10 lM) increased the GC activity
up to 1.9-fold (to ’36% of cellular WT GC activity) after a 5-d
treatment (Figure 1D, right panel). Diltiazem (20 lM)
increased G202R GC activity up to 4.6-fold (to ’46% of
cellular WT GC activity) after a 5-d incubation period (Figure
1E, green line), demonstrating the generality of diltiazem to
regulate GC protein homeostasis. Notably, diltiazem (20 lM)
increases WT GC activity up to 2.6-fold after 5 d of treatment
(Figure 1E, pink line), suggesting that the folding and
trafﬁcking of WT GC is inefﬁcient, as is the case for other
proteins such as G-protein-coupled receptors [42] and ion
channels [43].
The inﬂuence of diltiazem on the cellular activity of other
WT lysosomal hydrolases, namely a-mannosidase, a-glucosi-
dase, b-galactosidase, a-galactosidase, and b-glucuronidase
was evaluated. WT ﬁbroblasts and L444P GC ﬁbroblasts were
incubated with diltiazem (10 lM) for 5 d before the analysis
(Figure S2). While diltiazem treatment increased GC activity,
it did not signiﬁcantly increase the activity of other WT
lysosomal enzymes, implying that the folding and trafﬁcking
of these enzymes is near optimal.
A second L-type Ca
2þ channel blocker, verapamil (3 lM),
increased L444P GC activity up to 1.5-fold (to ’18% of
cellular WT GC activity) and N370S/V394L GC activity up to
1.9-fold (to ’53% of cellular WT GC activity) after a 7-d
incubation period (Figure 1F; lysed cell activity assay). That
both diltiazem and verapamil, which are Ca
2þ channel
blockers with distinct chemical structures (Figure 1B),
enhance cellular mutant GC folding, trafﬁcking, and activity
supports the hypothesis that altering intracellular Ca
2þ
homeostasis inﬂuences lysosomal enzyme homeostasis.
GC Exhibits a Dose-Dependent Concentration Increase
Upon Diltiazem Treatment
Western blot analysis reveals that L444P GC concentrations
were elevated in a dose-dependent manner in type II Gaucher
ﬁbroblasts after a 7-d treatment with diltiazem (Figure 2A). b-
actin served to ensure that equal amounts of total protein
were loaded in each lane. The GC band intensity increases
with the concentration of added diltiazem (0, 0.1, 1, and 10
lM), consistent with the observed dose-dependent increase in
GC enzymatic activity (Figure 1C, left panel).
The patient-derived N370S/V394L GC cell line was also
cultured with diltiazem (0.1–10 lM) for 7 d, revealing an
analogous dose-dependent increase in GC band intensity
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activity increase (Figure 1D, middle panel). An endo-H
digestion was performed on treated and untreated N370S/
V394L GC cells to demonstrate that the mature lysosomal
glycoform of GC, associated with proper lyososmal trafﬁck-
ing, was being produced. After 7 d of cell culturing, equal
numbers of diltiazem-treated (10 lM) and untreated cells
(reﬂected by equal amounts of total protein) were subjected
to endo-H treatment or buffer only treatment before
separation on a 10% SDS-PAGE gel and detection of GC by
Western blot analysis (Figure 2C). The upper bands in lanes 2
and 4 corresponding to the endo-H resistant, mature
lysosomal GC glycoform increase upon diltiazem treatment
[10], demonstrating that substantially more properly folded
GC protein was trafﬁcked out of the ER and to the lysosome
after diltiazem treatment. The lower bands in lanes 2 and 4
correspond to the endo-H sensitive, ER GC glycoform.
Ruling out a Pharmacological Chaperoning Mechanism
and a Direct Lysosomal GC Activation Mechanism
All of the GC pharmacological chaperones discovered to
date are active-site–directed stabilizers and are thus enzyme
inhibitors; therefore we evaluated whether diltiazem binds to
the active site and inhibits GC. Lysed L444P ﬁbroblasts and
Figure 2. Effect of Diltiazem on L444P and N370S/V394L GC Folding and Trafficking
(A) Western blot analysis of untreated and diltiazem-treated L444P GC cells. L444P GC cells were cultured without or with diltiazem at varying
concentrations for 7 d before the cells were lysed for SDS-PAGE and Western blot analysis. GC was detected using mouse anti-GC antibody 2E2. b-actin
served as a loading control.
(B) Western blot of untreated and diltiazem-treated N370S/V394L GC cells. N370S/V394L GC cells were incubated with variable diltiazem concentrations
for 7 d before the cells were lysed for SDS-PAGE and Western blot analysis using mouse anti-GC antibody 8E4.
(C) The endo-H sensitivity of untreated and diltiazem-treated N370S/V394L GC cells. N370S/V394L GC cells were incubated without and with 10 lM
diltiazem for 7 d before the cells were lysed for endo-H digestion, SDS-PAGE, and Western blot analysis using mouse anti-GC antibody 8E4.
(D) L444P and N370S/V394L GC cells were lysed and an equal amount of total cell protein was incubated with diltiazem and their GC activities were
evaluated using the lysed cell GC activity assay. Cerezyme, a recombinant WT GC protein, was also tested for its GC activity after treatment with
diltiazem (black line) or a pharmacological chaperone NN-DNJ, a known inhibitor (blue line).
(E) Quantitative RT-PCR on untreated and diltiazem-treated L444P and N370S/V394L GC cells. L444P and N370S/V394L GC cells were incubated with 10
lM diltiazem for 6 h, 12 h, 1 d, 3 d, and 5 d. The figure on the left is the representative amplification plot for the quantitative PCR cycles using L444P GC
cells; the figure on the right shows the relative GC mRNA expression level for diltiazem-treated L444P (left entries) and N370S/V394L GC cells (right
entries), respectively, which is normalized to that of untreated cells.
(F) Immunofluorescence colocalization analysis of GC in N370S/V394L GC and WT fibroblasts. N370S/V394L GC cells were incubated with 5 lM diltiazem
for 7 d (column 1) or cultured without drug (column 2). Untreated WT cells were observed as a positive control (column 3). GC was visualized using
mouse anti-GC antibody 16B3 (row 2) and rabbit anti-LAMP2 antibody was applied as a lysosomal marker (row 1). In row 3, the colocalization of GC
(green) and LAMP2 (red) is shown in white. Bar ¼ 10 lm.
(G) Immunofluorescence colocalization analysis of GC in L444P GC cells. L444P GC cells were incubated with 10 lM diltiazem for 14 d (bottom row) or
untreated (top row). GC visualization was accomplished using the mouse anti-GC antibody 8E4 (column 1); rabbit anti-LAMP2 antibody was used as a
lysosomal marker (column 2). In column 3, the colocalization of GC (green) and LAMP2 (red) is artificially colored white. Bar ¼ 20 lm.
(H) Quantification of the colocalization between the GC protein and the lysosomal marker using PCC. Experimental conditions were stated in Figure 2F.
doi:10.1371/journal.pbio.0060026.g002
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to 1000 lM) and assayed. No signiﬁcant GC inhibition was
observed in either case (Figure 2D, pink and green lines).
Cerezyme, a recombinant version of WT GC, was also
incubated with diltiazem (0.01–1000 lM), revealing lack of
inhibition (Figure 2D, black line). As a positive control, an
established GC pharmacological chaperone—N-(n-nonyl)-
deoxynojirimycin (NN-DNJ), exhibiting a half maximal
inhibitory concentration (IC50) value of 1.08 lM toward
Cerezyme (Figure 2D, blue line)—exhibited inhibition [14].
Collectively, these results demonstrate that diltiazem does not
bind to the active site of GC ex vivo and is unlikely to
function as a pharmacological chaperone.
To evaluate whether diltiazem could directly activate the
existing lysosomal GC pool, L444P and N370S/V394L GC
ﬁbroblasts were incubated with diltiazem (1–100 lM) for 1 h,
andtheGCactivitywasmeasuredusingtheintactcellassay.No
activity increase was observed (Figure S3), demonstrating that
the GC activity increase could not be achieved on this short
time scale, a result inconsistent with direct diltiazem-induced,
saposin-mediated activation of GC. A relatively long incuba-
tion period (5 d) is required to maximally increase intra-
lysosomalL444PGCactivity2.0-fold(Figure1C,leftpanel)and
N370S/V394L GC activity 3.2-fold (Figure 1D, middle panel),
suggesting that diltiazem likely requires new GC synthesis to
achieve enhanced GC activity, consistent with the nearly
identical rates of GC activity increases mediated by diltiazem
treatment and pharmacological chaperone treatment [17].
Diltiazem Does Not Influence GC Transcription
Quantitative reverse transcription (RT) PCR analysis was
performed on L444P GC ﬁbroblasts incubated without and
with 10 lM diltiazem for 6 h, 12 h, 1 d, 3 d, and 5 d. Real-time
PCR reactions were performed on total DNA reverse-tran-
scribed from total RNA samples, which were extracted from
L444P GC-harboring cells. The PCR ampliﬁcation plot is
shown in Figure 2E, left panel. DCT is deﬁned as the difference
between the threshold cycle (CT) value of the GC gene and the
CT value of a housekeeping gene. The relative GC mRNA
expression level was normalized to that of untreated GC cells,
calculated from corresponding DCT values (see Materials and
Methods). No signiﬁcant differences for the GC mRNA
expression levels were observed when comparing untreated
and diltiazem-treated L444P GC cells (Figure 2E, right panel,
left entries) demonstrating that diltiazem does not inﬂuence
GC transcription in L444P GC cells. Strictly analogous results
were obtained for diltiazem-treated N370S/V394L GC cells
(Figure 2E, right panel, right entries).
Diltiazem Enhances Proper GC Folding and Trafficking
Cellular trafﬁcking of L444P and N370S/V394L GC appears
to be reduced because of ERAD outcompeting folding and
trafﬁcking [9]. Fluorescence microscopy was previously used
to demonstrate that active-site–directed pharmacological
chaperones enhance the folding and trafﬁcking of G202R
GC to the lysosome [10]. Strictly analogous immunoﬂuor-
escence microscopy methods were used to demonstrate that
Ca
2þ channel blockers increase L444P and N370S/V394L GC
trafﬁcking to the lysosome. L444P GC harboring ﬁbroblasts
were cultured without or with 10 lM diltiazem for 14 d before
plating for microscopy. WT GC ﬁbroblasts were also studied
analogously as a positive control. A properly folded and
trafﬁcked GC protein will colocalize with the lysosomal
marker LAMP2 [10]. WT GC distributed in a punctate
manner, and colocalized with LAMP2 (Figure 2F, column 3,
row 3, GC in green, LAMP2 in red, and overlap artiﬁcially
colored white). This color scheme is used only for the
colocalization row; for single staining experiments (the ﬁrst
two rows), the ﬂuorescence images are artiﬁcially colored
white to improve contrast. While the L444P GC variant was
not visible without diltiazem treatment, due to extensive
ERAD, it was easily detected and was distributed in a punctate
manner after diltiazem treatment (Figure 2G, column 1).
L444P GC colocalized with LAMP2 after diltiazem treatment
(Figure 2G, column 3, GC in green, LAMP2 in red, and
overlap artiﬁcially colored white), indicating increased
lysosomal trafﬁcking, consistent with the increase in cellular
GC concentrations (Figure 2A) and the increase in enzymatic
activity (Figure 1C).
Previous experiments demonstrate that the N370S GC
distribution is partially lysosomal [10]. To determine whether
the increase in properly glycosylated N370S/V394L GC
protein that was observed in response to diltiazem treatment
(Figure 2C) resulted in an increase in proper trafﬁcking to the
lysosome, quantitative immunoﬂuorescence microscopy was
performed. N370S/V394L GC ﬁbroblasts were incubated
without and with 5 lM diltiazem for 7 d before plating for
microscopy. WT GC ﬁbroblasts served as a control. While
measurable N370S/V394L GC colocalizes with the lysosome,
there is substantially less N370S/V394L GC in the lysosome in
comparison to WT GC (Figure 2F, compare column 2 with
column 3), consistent with signiﬁcant ERAD. Diltiazem
treatment notably enhanced N370S/V394L GC trafﬁcking to
the lysosome (Figure 2F, compare column 1 with column 2),
consistent with its ability to increase the concentration of the
mature GC glycoform, Figure 2B and 2C. Quantiﬁcation of
the colocalization between the GC protein and the lysosomal
marker using twenty random microscope ﬁelds for each
sample was accomplished using Pearson’s correlation coef-
ﬁcient (PCC). WT GC, untreated N370S/V394L GC, and
diltiazem-treated N370S/V394L GC ﬁbroblasts have PCC
values of 0.70 6 0.06, 0.60 6 0.05, and 0.68 6 0.05,
respectively (Figure 2H). The difference between the PCC
values of untreated and diltiazem-treated N370S/V394L GC
cells is signiﬁcant (p , 0.001, n ¼ 20), demonstrating that
diltiazem increased trafﬁcking of N370S/V394L GC to the
lysosome, nearly to WT levels.
Extracellular Ca
2þ Concentration Influences Intracellular
Folding Capacity
Diltiazem and verapamil are both potent L-type voltage-
gated calcium channel blockers that inhibit Ca
2þ entry from
the extracellular medium into the cell and thus alter calcium
homeostasis in the cell [35]. The cytoplasmic free Ca
2þ ion
concentration (;100 nM) is much lower than the extracellular
Ca
2þ ion concentration (;2 mM) at steady state in a normal
cellular environment. We explored whether manipulation of
the extracellular Ca
2þ concentration for prolonged periods
could alter intracellular GC folding, trafﬁcking and activity.
Different Ca
2þ ion concentrations (0, 0.5, 1, 1.5, and 2 mM
CaCl2) added to Ca
2þ-free cell culture media (supplemented
with fetal bovine serum) were applied to L444P GC cells for
10 d and to N370S/V394 GC cells for 7 d. The GC activity was
then evaluated using the lysed cell GC activity assay. GC
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2þ
added in the media, similar to the concentration used in
other experiments reported in this paper. The maximum GC
activity increase (1.5-fold) was achieved when 1 mM Ca
2þ was
added to the media of L444P and N370S/V394L GC cells,
demonstrating the important inﬂuence of extracellular Ca
2þ
ion concentration on GC folding and trafﬁcking (Figure 3A).
Whether Ca
2þ ions can interact directly with the GC
protein was explored. Lysed L444P and N370S/V394L GC
cells were incubated with variable Ca
2þ ion concentrations
(25 nM to 2 mM) and assayed using the lysed cell GC activity
assay, indicating no signiﬁcant changes in GC activity (Figure
3B). Cerezyme, a recombinant version of WT GC, was
evaluated analogously, revealing unaltered activity (Figure
3B, black line). These results demonstrate that Ca
2þ ions do
not directly activate or inhibit the GC protein ex vivo.
GC Activity Enhancement Correlates with Ca
2þ Ion
Channel Blocker Activity
To further examine the hypothesis that diltiazem enhances
GC activity through its Ca
2þ ion channel blocker activity, ﬁve
diltiazem analogs exhibiting a range of potencies were
Figure 3. Intracellular Ca
2þ Ion Concentration Influences GC Activity in L444P and N370S/V394L GC Fibroblasts
(A) Variable Ca
2þion cell culture media concentrations were applied to L444P GC cells for 10 d and to N370S/V394 GC cells for 7 d before using the lysed
cell GC activity assay. The GC activity was normalized to that with 2 mM Ca
2þ added in the media in both cases.
(B) L444P and N370S/V394L GC cells were lysed and an equal amount of total cell protein was incubated with Ca
2þ ions and their GC activities were
evaluated using the lysed cell GC activity assay. Cerezyme, a recombinant WT GC enzyme, was also tested for its activity after Ca
2þ treatment.
(C) Chemical structure of diltiazem analogs (compounds 2–6; distinct substructures relative to compound 1 are shown in red) with their reported Ca
2þ
channel blocker IC50 values [44].
(D) The influence of Ca
2þ ion channel blockers of varying potency on L444P GC activity. L444P GC cells were incubated with compounds 1–6 for 7 d
before using the intact cell GC activity assay to evaluate lysosomal GC activity.
(E) The influence of Ca
2þ ion channel blockers of varying potency on N370S/V394L GC activity. N370S/V394L GC cells were incubated with compounds
1–6 for 7 d before evaluating GC activity using the intact cell activity assay. For both (D) and (E), the GC activity of treated cells was normalized against
that of untreated cells of the same type (left y-axis) and expressed as the percentage of WT GC activity (right y-axis).
doi:10.1371/journal.pbio.0060026.g003
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2þ channel
blocker IC50 values are: 1 (diltiazem, IC50¼0.98 lM) . 2 (2.46
lM) . 3 (45.5 lM) . 4 (126.7 lM) [44]. Analogs 5 and 6 should
not block Ca
2þ ion channel activity because they lack a key
basic amino nitrogen pharmacophore linked to N5 in the
benzothiazepine ring scaffold, according to a reported
structure-activity relationship (SAR) study on benzazepinone
[45] and a quantitative SAR study on diltiazem [46].
L444P GC ﬁbroblasts were cultured with compounds 1–6
(0.3–100 lM) for 7 d, and dose-response curves were recorded
using the intact cell GC activity assay (Figure 3D). Com-
pounds 1 (IC50 ¼ 0.98 lM) and 2 (IC50 ¼ 2.46 lM) are potent
Ca
2þ channel antagonists and exhibit notable L444P lysoso-
mal GC activity increases to a maximum of 2.3-fold for 1 and
2.1-fold for 2 at 10 lM (Figure 3D, black lines). Compounds 3
(IC50 ¼ 45.5 lM) and 4 (IC50 ¼ 126.7 lM) are both weak Ca
2þ
channel antagonists and weak L444P GC activity enhancers.
Notably, only at much higher concentrations (30 lM) do
these low-potency analogs exhibit a maximum increase in
L444P GC activity of 1.3-fold for 3 and 1.2-fold for 4 (Figure
3D, pink lines). Compounds 5 and 6 are not Ca
2þ channel
antagonists, and, as such, these closely related analogs do not
increase L444P GC activity (Figure 3D, green lines). These
data demonstrate that the more potent the Ca
2þ ion channel
blocker, the higher the lysosomal GC activity enhancement
observed. Diltiazem and its analogs reveal analogous results
in N370S/V394L ﬁbroblasts (Figure 3E). Compound 1 (10 lM)
increased N370S/V394L GC activity to a maximum of 3.6-
fold, whereas compound 2 (10 lM) afforded a 2.8-fold
increase, more than the increases observed with L444P cells.
High concentrations of compounds 5 and 6 (.10 lM) are
toxic to both L444P and N370S/V394L ﬁbroblasts. At 100 lM,
compounds 1–4 also lower GC activity due to cytotoxicity.
To further investigate the idea that diltiazem enhances GC
activity by blocking plasma membrane Ca
2þ ion channels,
thus lowering intracellular Ca
2þ concentrations, thapsigar-
gin—a potent SERCA inhibitor—was applied to L444P GC
cells without or with 10 lM diltiazem for 7 d. Thapsigargin
inhibits Ca
2þ entry into the ER from the cytosol, presumably
leading to an increase in intracytoplasmic Ca
2þ ion concen-
trations [33]. Therefore, diltiazem and thapsigargin have
opposite effects on regulating cytosolic calcium homeostasis.
Thapsigargin alone had no inﬂuence on GC activity until a
concentration of 1 nM was reached; above this concentration,
thapsigargin decreased L444P GC activity signiﬁcantly after
7-d incubation (Figure S4, pink line). Co-application of
varying concentrations of thapsigargin with 10 lM diltiazem
revealed a thapsigargin dose-dependent decrease of GC
activity (Figure S4, blue line), consistent with the hypothesis
that these compounds have opposite inﬂuences on cytoplas-
mic Ca
2þ ion levels and that lower rather than higher
intracellular Ca
2þ levels enhance mutant GC homeostasis.
Diltiazem Treatment Up-Regulates the Expression of
Chaperones
Molecular chaperones are known to be essential for the
maintenance of cellular protein homeostasis [2,47–49]; hence
it is possible that elevated chaperone expression levels could
be responsible for the observed diltiazem-mediated enhance-
ment in lysosomal enzyme homeostasis. Quantitative RT-PCR
analysis was performed on L444P GC ﬁbroblasts incubated
without and with 10 lM diltiazem for 1 d and 7 d. The relative
mRNA expression levels of representative cytoplasmic and
ER lumenal chaperones—including Hsp40, Hsp70, BiP,
Hsp90, GRP94, calnexin, calreticulin, HIP, and HOP—were
probed and normalized to the levels found in untreated cells
(Figure 4A). The large ribosomal protein (RiboP) was
monitored as a control. All the primer pairs used are listed
in Table S1. The mRNA expression levels of BiP, Hsp40, and
Hsp90 were increased up to 1.8-fold, 1.8-fold, and 1.9-fold,
respectively, after a 7-d treatment with diltiazem, whereas the
mRNA expression levels of Hsp70, GRP94, calnexin, and
calreticulin were not changed signiﬁcantly. A strictly analo-
gous RT-PCR analysis of N370S/V394L GC ﬁbroblasts reveals
similarly increased mRNA expression levels of Hsp40,
however BiP and Hsp90 exhibit less of an increase after 7 d
of diltiazem treatment (Figure S5). Western blot analysis was
also performed on L444P GC ﬁbroblasts incubated without
and with diltiazem (10 lM) for 4 d and 7 d (Figure 4B). The
increased protein expression levels of BiP, Hsp40, and Hsp90
were conﬁrmed after a 7-d treatment with diltiazem. That the
expression levels of GRP94, Hsp70, calnexin, and calreticulin
were not changed signiﬁcantly was also conﬁrmed at the
protein level. These increases in molecular chaperone
expression levels, especially the cytoplasmic Hsp40 levels,
seem to account for the increased GC folding capacity of the
Figure 4. Chaperone Expression Level in Untreated and Diltiazem-
Treated L444P GC Fibroblasts
(A) Quantitative RT-PCR on untreated and diltiazem-treated L444P GC
cells. L444P GC cells were incubated with 10 lM diltiazem for 1 d and 7 d.
Relative mRNA expression level for diltiazem-treated L444P GC cells was
normalized to that of untreated cells. Hsp40, Hsp70, Hsp90, HIP, HOP,
BiP, GRP94, calnexin, and calreticulin were probed using corresponding
primer pairs. Large ribosomal protein (RiboP) served as a housekeeping
control.
(B) L444P GC cells were treated with 10 lM diltiazem for 4 d and 7 d
before being lysed for SDS-PAGE analysis. Hsp40, Hsp70, Hsp90, BiP,
GRP94, calnexin, and calreticulin were probed using Western blot
analysis. b-actin served as a loading control.
doi:10.1371/journal.pbio.0060026.g004
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contribute to the relatively slow increases in lysosomal
enzyme levels upon calcium channel blocker treatment.
Given the highly dynamic nature of the ER, it is envisioned
that the cytosolic chaperones play a role in creating an ER
optimized for protein folding and trafﬁcking.
Ca
2þ Channel Blockers Improve Enzyme Homeostasis in
Two Additional Lysosomal Storage Diseases Associated
with Glycoprotein and Heparan Sulfate Accumulation
Lysosomal a-mannosidase is a broad-speciﬁcity exoglyco-
sidase involved in the ordered degradation of glycoproteins
[24]. The P356R mutation in the a-mannosidase enzyme
appears to compromise folding and trafﬁcking, leading to
very low lysosomal a-mannosidase activity and severe a-
mannosidosis [26]. The activity of cells harboring P356R a-
mannosidase is approximately 18% of that of WT a-
mannosidase, under the assay conditions used. Incubation
of these cells with a range of diltiazem or verapamil
concentrations for 1, 4, 7, and 10 d enabled lysed cell enzyme
activity analysis to be performed. Diltiazem (35 lM) increased
the P356R a-mannosidase activity up to 2.0-fold after 7-d
incubation period (’36% the activity of WT a-mannosidase;
Figure 5A). Verapamil (50 lM) increased the P356R a-
mannosidase activity up to 3.1-fold (’56% the activity of
WT a-mannosidase) after an incubation period of 4 d (Figure
5B). Brief exposure of P356R a-mannosidase harboring cells
to diltiazem or verapamil (1 d) did not increase a-mannosi-
dase activity signiﬁcantly (Figure 5A and 5B), indicating that
it is likely that new protein synthesis is required for diltiazem
and verapamil to affect cellular protein homeostasis, con-
sistent with the result obtained from the Gaucher cell lines
described above (Figure 1 and Figure S3).
The MPS type IIIA LSD is caused by a deﬁciency of SGSH,
Figure 5. The Influence of Diltiazem and Verapamil on Mutant a-Mannosidase and Heparan Sulfate Sulfamidase (SGSH) Activity in Patient-Derived
Fibroblasts
The enzyme activity of treated cells was normalized against that of untreated cells of the same type (left y-axis) and expressed as the percentage of WT
enzyme activity (right y-axis).
(A) The influence of diltiazem on P356R a-mannosidase activity after culturing for 1 d (black line), 4 d (pink line), 7 d (blue line), and 10 d (yellow line).
(B) The influence of verapamil on P356R a-mannosidase activity after culturing for 1 d (black line), 4 d (pink line), 7 d (blue line), and 10 d (yellow line).
(C) The influence of diltiazem (pink line) and verapamil (green line) on S66W/V131M SGSH activity after culturing for 5 d.
(D) The influence of diltiazem (pink line) and verapamil (green line) on R245H/E447K SGSH activity after culturing for 5 d, respectively. Unlike in Figure 1
and 3, percent activity relative to WT in Figure 5C and 5D is calculated from the specific activity of S66W and R245H reported in the literature [27].
doi:10.1371/journal.pbio.0060026.g005
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Protein Homeostasis Restorationresulting in the defective degradation and storage of heparan
sulfate, a glycosaminoglycan [25]. The common S66W and
R245H mutations in type IIIA MPS lead to reduced speciﬁc
activity (15% and 83% of normal speciﬁc activity for S66W
and R245H, respectively) and lower cellular concentrations,
likely a result of compromised folding and trafﬁcking of the
sulfamidase variants to the lysosome [27]. Two compound
heterozygous MPS cell lines were used to evaluate the effect
of diltiazem or verapamil, using an intact cell enzyme activity
assay. In the case of the S66W/V131M MPS cells, diltiazem (50
lM) or verapamil (10 lM) treatment increased S66W/V131M
sulfamidase activity up to 2.1-fold and 1.9-fold (’30 % of WT
sulfamidase activity), respectively, after a 5-d treatment,
(Figure 5C). In the case of R245H/E447K MPS cells, diltiazem
(25 lM) increased R245H/E447K SGSH activity up to 2.5-fold
(’207 % of WT sulfamidase activity), whereas verapamil did
not change the sulfamidase activity signiﬁcantly after 5-d
treatment (Figure 5D).
Discussion
We report the discovery that the L-type Ca
2þ channel
blockers diltiazem and verapamil restore partial folding,
trafﬁcking, and enzyme function to patient-derived ﬁbro-
blasts in three distinct LSDs, disorders involving deﬁciencies
in nonhomologous lysosomal enzymes that perform distinct
chemical reactions. That these Ca
2þchannel blockers are both
FDA-approved drugs provides the incentive to conduct
further necessary efﬁcacy and safety experiments to discern
whether they are promising candidates to ultimately treat
neuropathic GD and related LSDs. Fortunately, diltiazem
crosses the blood-brain barrier [50] and is bioavailable in the
lM concentration range in blood plasma [51].
The Ca
2þ ion channel blocker potency of diltiazem and its
analogs correlates with their efﬁciency to enhance GC folding
in the ER, enabling trafﬁcking and the lysosomal localization
of mutant GC in patient-derived ﬁbroblast cell lines [52]. But
how is the blockage of L-type Ca
2þ channels on the plasma
membrane by diltiazem coupled to enhanced mutant GC
homeostasis? Activation of these channels allows extracellular
Ca
2þ to enter the cytosol, which subsequently induces further
Ca
2þion release from intracellular Ca
2þstores, such as the ER,
by activating ryanodine receptors, the Ca
2þ ion channels
within the ER membrane. Inhibiting this calcium-induced
calcium release [53] pathway minimizes depletion of the ER
Ca
2þ store, a process that appears to up-regulate the
expression of a subset of cytosolic and ER chaperones,
especially Hsp40. How blockage of L-type Ca
2þ channels on
the plasma membrane by diltiazem and verapamil inﬂuences
gene transcription in the nucleus is unclear, and this
signaling cascade merits further investigation.
Others have reported that the reduction in ER Ca
2þ ion
concentrations by SERCA inhibitors, such as curcumin [34]
and thapsigargin [33], enhance folding and trafﬁcking of
DF508 CFTR. However, thapsigargin does not enhance L444P
GC folding, trafﬁcking, or lysosomal activity (Figure S4). Nor
does diltiazem treatment increase the trafﬁcking of DF508
CFTR to the plasma membrane (William E. Balch, personal
communication). Diltiazem blocks calcium entry into the
cytosol, whereas thapsigargin inhibits calcium movement
from the cytosol into the ER. Therefore, diltiazem and
thapsigargin regulate calcium homeostasis oppositely, pre-
sumably explaining why diltiazem and thapsigargin partially
correct defective protein homeostasis in GD and cystic
ﬁbrosis, respectively.
Diltiazem is an FDA-approved small molecule used to treat
angina and hypertension marketed under names including
Cardizem, Dilacor, and Tiazec. Unlike pharmacological
chaperones that directly bind to GC, thus stabilizing the
folded enzyme in the ER for trafﬁcking to the Golgi and on to
the lysosome, diltiazem treatment of ﬁbroblasts derived from
patients with GD appears to alter the biological folding
capacity of the ER. Diltiazem is well-tolerated, and the
incidence of side effects is low. Its pharmacological proper-
ties have been extensively studied and reviewed [51,54,55].
Whereas diltiazem exhibited its best efﬁcacy at increasing GC
activity in patient-derived ﬁbroblasts when used at a culture
concentration of 10 lM, its lowest effective cell culture media
concentration is in the range of 0.1–1 lM (Figures 2 and 3),
equivalent to human plasma levels achieved by oral dosing.
Summary
Diltiazem and verapamil, potent FDA-approved L-type
Ca
2þ channel blocker drugs, increased the ER folding
capacity, trafﬁcking, and activity of mutant lysosmal enzymes
associated with three distinct LSDs. These compounds likely
act through a Ca
2þ ion mediated up-regulation of a subset of
cytoplasmic and ER lumenal chaperones. Increasing ER
calcium levels appears to be a relatively selective strategy to
partially restore mutant lysosomal enzyme homeostasis in
patient-derived cells, as DF508 CFTR folding efﬁciency and
the folding efﬁciency of several other cellular WT enzymes
was unaffected by these Ca
2þ channel blockers.
Materials and Methods
Reagents. Diltiazem hydrochloride (1) and verapamil were from
Tocris Bioscience. Compound 2 was from Synﬁne. Compounds 3 and
4 were synthesized as described in Text S1. Ruthenium red,
compounds 5 and 6, 4-methylumbelliferyl b-D-glucopyranoside, 4-
methylumbelliferyl a-D-mannopyranoside, 4-methylumbelliferyl a-D-
glucopyranoside, 4-methylumbelliferyl b-D-galactopyranoside, 4-
methylumbelliferyl a-D-galactopyranoside, and 4-methylumbelliferyl
b-D-glucuronide were from Sigma. N-(n-nonyl)deoxynojirimycin
(NN-DNJ), Conduritol B epoxide (CBE), and 4-methylumbelliferyl 2-
sulfamino-2-deoxy-a-D-glucopyranoside were from Toronto Re-
search Chemicals. All the other tested small molecules were either
from Tocris Bioscience or from Sigma. Cell culture media were
obtained from Gibco. Human injection-quality recombinant WT GC
protein (trade name Cerezyme) was obtained from Genzyme.
Cell cultures. Primary skin ﬁbroblast cultures were established
from patients with GD who were homozygous for either the N370S
GC (1226A.G) mutation or the G202R GC (721G.A) mutation. An
apparently normal ﬁbroblast (GM00498), three distinct homozygous
Gaucher ﬁbroblasts containing the L444P GC (1448T.C) mutation
(GM08760, GM10915, and GM20272), two compound heterozygous
Gaucher ﬁbroblasts containing the N370S/V394L GC mutation
(GM01607) and N370S/84GG GC mutation (GM00372), a homozygous
a-mannosidosis ﬁbroblast containing the P356R a-mannosidase
mutation (GM04518), and two compound heterozygous type IIIA
mucopolysaccharidosis ﬁbroblasts containing the S66W/V131M
SGSH mutation (GM01881) and R245H/E447K SGSH mutation
(GM00879) were obtained from the Coriell Cell Repositories.
Fibroblasts were maintained in minimum essential medium with
Earle’s salts supplemented with 10% heat-inactivated fetal bovine
serum and 1% glutamine Pen-Strep at 37 8Ci n5 %C O 2.
Enzyme activity assays. The intact cell GC activity assay has been
previously described [14]. Brieﬂy, cells were plated into 48-well assay
plates (500 ll per well). After cell attachment, the media was
replaced by media containing small molecules. Media was changed
every 3 d. After incubation at 37 8C for the indicated amount of
time, the intact cell GC activity assay was performed. The
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addition of 150 ll of 3 mM 4-methylumbelliferyl b-D-glucopyrano-
side in 0.2 M acetate buffer (pH 4.0) to each well, followed by
incubation at 37 8C for 1–7 h. CBE was used as a control to evaluate
the extent of nonspeciﬁc GC activity. The reaction was stopped by
lysing the cells with 750 ll of 0.2 M glycine buffer (pH 10.8).
Liberated 4-methylumbelliferone was measured (excitation 365 nm,
emission 445 nm) with a SpectraMax Gemini plate reader (Molecular
Devices). The lysed cell GC activity assay has been previously
described [14]. Brieﬂy, intact cells were harvested and the pellet
was lysed in the complete lysis-M buffer containing complete
protease inhibitor cocktails (Roche #10799050001). Total cell protein
was measured using the Micro BCA assay reagent (Pierce #23235).
Thirty lg of total cell protein was assayed for the GC activity in 100
ll of 0.1 M acetate buffer (pH 5.0) containing 3 mM 4-methyl-
umbelliferyl b-D-glucopyranoside in the presence of 0.15% Triton
X-100 (v/v, Fisher) and 0.15% taurodeoxycholate (w/v, Calbiochem).
CBE was used as a control to evaluate the extent of nonspeciﬁc GC
activity. After incubation at 37 8C for 1–7 h, the reaction was
terminated with 200 ll of 0.2 M glycine buffer (pH 10.8), and the
ﬂuorescence was recorded (excitation 365 nm, emission 445 nm).
The GC activity assay for recombinant WT GC enzymes has been
previously described [10]. 25 ng of recombinant WT GC protein was
assayed for the GC activity in 50 ll of 0.1 M acetate buffer (pH 5.0)
containing 3 mM 4-methylumbelliferyl b-D-glucopyranoside in the
presence of 0.15% Triton X-100 (v/v, Fisher) and 0.15% taurodeox-
ycholate (w/v, Calbiochem). After the addition of tested compounds,
the reaction was incubated at 37 8C for 20 min, terminated with 75 ll
of 0.2 M glycine buffer (pH 10.8), and the ﬂuorescence was recorded
(excitation 365 nm, emission 445 nm).
The activity of lysosomal a-mannosidase was determined as
previously described with minor modiﬁcation by using 2 mM 4-
methylumbelliferyl a-D-mannopyranoside as the substrate [26]. The
activity of lysosomal SGSH was determined by using 0.5 mM 4-
methylumbelliferyl 2-sulfamino-2-deoxy-a-D-glucopyranoside as pre-
viously described with minor modiﬁcation [56]. The activities of
lysosomal enzymes a-glucosidase, b-galactosidase, a-galactosidase,
and b-glucuronidase were assayed as previously described by using
corresponding substrates 4-methylumbelliferyl a-D-glucopyranoside,
4-methylumbelliferyl b-D-galactopyranoside, 4-methylumbelliferyl a-
D-galactopyranoside, and 4-methylumbelliferyl b-D-glucuronide,
respectively [17].
Small molecules were evaluated at least in triplicate at each
concentration, and each molecule was assayed at least three times.
The data reported were normalized to the enzyme activity of
untreated cells of the same type and expressed as percentage of
WT enzyme activity.
Quantitative RT-PCR. The cells were incubated with 10 lM
diltiazem at 37 8C for the indicated amount of time. Total RNA was
extracted from the cells using RNeasy Mini Kit (Qiagen #74104).
cDNA was synthesized from 500 ng of total RNA using QuantiTect
Reverse Transcription Kit (Qiagen #205311). Quantitative PCR
reactions were performed using QuantiTect SYBR Green PCR Kit
(Qiagen #204143) and corresponding primers in the ABI PRISM 7900
system (Applied Biosystems). The forward and reverse primers for
GC, Hsp40, Hsp70, Hsp90, HIP, HOP, BiP, GRP94, calnexin (CNX),
and calreticulin (CRT), and an endogenous housekeeping gene large
ribosomal protein (RiboP) are listed in Table S1. Samples were heated
for 15 min at 95 8C and ampliﬁed in 45 cycles of 15 s at 94 8C, 30 s at
59 8C, and 30 s at 72 8C. Analysis was done using SDS2.1 software
(Applied Biosystems). Threshold cycle (CT) was extracted from the
PCR ampliﬁcation plot. The DCT value was used to describe the
difference between the CT of a target gene and the CT of the
housekeeping gene: DCT¼CT (target gene) – CT (housekeeping gene).
The relative mRNA expression level of a target gene of diltiazem-
treated cells was normalized to that of untreated cells: Relative mRNA
expression level ¼ 2 exp [–(DCT (treated cells) – DCT (untreated
cells))].
Western blot. The cells were lysed using the complete lysis-M
buffer containing complete protease inhibitor cocktails (Roche
#10799050001). Total cell protein was measured using the Micro
BCA assay reagent. Endo H (New England Biolabs #P0703) was used
to digest the cell lysates according to the company instructions. The
cell lysates containing equal amount of total protein were separated
by 10% SDS-PAGE. Western blot analysis was performed with proper
antibodies. Mouse monoclonal anti-GC 8E4 [57] was kindly provided
by Klaus-Peter Zimmer (Children’s Hospital of the University of
Mu ¨nster, Mu ¨nster, Germany). Mouse monoclonal anti-GC 2E2 was
from Novus Biologicals (#H00002629-M01). Antibodies directed
against calnexin (#SPA-860), calreticulin (#SPA-601), Hsp40 (#SPA-
400), Hsp70 (#SPA-812), and Hsp90 (#SPA-830) were from Stressgen.
Antibodies directed against BiP (#SC-13968) and GRP94 (#SC-11402)
were from Santa Cruz Biotechnology. Mouse monoclonal anti-b actin
AC-15 was from Sigma (#A1978). Secondary antibodies (#31430 for
goat anti-mouse and #31460 for goat anti-rabbit) were from Pierce.
Bands were visualized using the SuperSignal West Pico Chemilumi-
nescent Substrate (Pierce #34078) or SuperSignal West Femto
Maximum Sensitivity Substrate (Pierce #34095).
Immunoﬂuorescence. Immunoﬂuorescence has been previously
described [10]. Cells grown on glass cover slips were washed by PBS
and ﬁxed with 3.7% paraformaldehyde in PBS for 15 min. The slips
were washed with PBS, quenched with 15 mM glycine in PBS for 10
min, and permeabilized with 0.2% saponin in PBS for 15 min. The
antibodies were prepared in PBS in the presence of 0.2% saponin
and 5 % goat serum. Cells were incubated for 1 h with primary
antibodies (1:100 for mouse monoclonal anti-GC 16B3 [58] (kindly
provided by Ernest Beutler, The Scripps Research Institute, La Jolla,
CA), or 1:100 for 8E4, and 1:10,000 for rabbit anti-LAMP2 [59] (kindly
provided by Michiko Fukuda, The Burnham Institute, La Jolla, CA)),
washed with 5 % goat serum in PBS, and then incubated for 1 h with
secondary antibodies (Alexa Fluor 488 goat anti-mouse IgG (#A11029)
and Alexa Fluor 546 goat anti-rabbit IgG (#A11035)) from Molecular
Probes. The cover slips were mounted and sealed. Images were
collected using a Bio-Rad (Zeiss) Radiance 2100 Rainbow laser
scanning confocal microscope attached to a Nikon TE2000-U
microscope. For quantitative colocalization analysis, Z-stacks of each
frame were ﬂattened, and PCC was calculated using NIH Image J
software. Random frames from each slide were averaged and
colocalization differences were analyzed using a two-tailed Student’s
t-test.
Supporting Information
Figure S1. The Inﬂuence of Ruthenium Red on L444P GC Activity in
Gaucher Patient-Derived Fibroblasts after Culturing for 1 d (Black
Line), 3 d (Pink Line), and 5 d (Green Line)
The GC activity of treated cells was normalized against that of
untreated L444P GC cells (left y-axis) and expressed as the percentage
of WT GC activity (right y-axis).
Found at doi:10.1371/journal.pbio.0060026.sg001 (42 KB PDF).
Figure S2. The Inﬂuence of Dilitazem on the Activity of Lysosomal
Enzymes
After incubation with 10 lM diltiazem for 5 d, WT ﬁbroblasts were
assayed for the activities of GC, a-mannosidase, a-glucosidase, and b-
galactosidase using intact cell enzyme activity assay, and L444P GC
cells were assayed for the activities of GC, a-mannosidase, a-
glucosidase, b-galactosidase, a-galactosidase, and b-glucuronidase
using lysed cell enzyme activity assay. The enzyme activity of treated
cells was normalized against that of untreated cells of the same type.
Found at doi:10.1371/journal.pbio.0060026.sg002 (45 KB PDF).
Figure S3. L444P and N370S/V394L GC Cells Were Incubated with
Diltiazem for 1 h, and Their GC Activities Were Evaluated Using the
Intact Cell GC Activity Assay
The GC activity of treated cells was normalized against that of
untreated cells of the same type.
Found at doi:10.1371/journal.pbio.0060026.sg003 (40 KB PDF).
Figure S4. The Inﬂuence of Thapsigargin and Diltiazem on GC
Activity in L444P GC Fibroblasts
Thapsigargin was applied without or with 10 lM diltiazem for 7 d.
The GC activity of treated cells was normalized against that of
untreated L444P GC cells (left y-axis) and expressed as the percentage
of WT GC activity (right y-axis).
Found at doi:10.1371/journal.pbio.0060026.sg004 (45 KB PDF).
Figure S5. Quantitative RT-PCR Analysis on Untreated and Diltia-
zem-Treated N370S/V394L GC Cells
N370S/V394L GC cells were incubated with 10 lM diltiazem for 1 d
and 7 d, respectively. Relative mRNA expression level for diltiazem-
treated N370S/V394L GC cells was normalized to that of untreated
cells. Hsp40, Hsp70, Hsp90, HIP, HOP, BiP, GRP94, calnexin (CNX),
and calreticulin (CRT) were probed using corresponding primer
pairs. Large ribosomal protein (RiboP) served as a housekeeping gene
control.
Found at doi:10.1371/journal.pbio.0060026.sg005 (35 KB PDF).
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Protein Homeostasis RestorationTable S1. Primer Sequences Used in Quantitative RT-PCR
Found at doi:10.1371/journal.pbio.0060026.st001 (46 KB DOC).
Text S1. Syntheses and Structural Characterization of Compounds 3
and 4
Found at doi:10.1371/journal.pbio.0060026.sd001 (61 KB DOC).
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